Diabetes PubMed

In a large meta-analysis, vildagliptin was not associated with an increased risk of adjudicated cardiovascular and cerebrovascular (CCV) events relative to all comparators in the broad population of type 2 diabetes including patients at increased risk of CCV events.

Because vildagliptin does not expose patients to hypoglycaemic risk, it seems particularly suited to oral therapy of T2DM in the elderly.

The addition of vildagliptin to metformin therapy during Ramadan in Muslim patients with type 2 diabetes was associated with a reduction in the incidence of hypoglycaemia.

Vildagliptin therapy but not glimepiride improves post-prandial alpha-cell function, which persists for at least 2 years.

Although the hypothesis of noninferiority to gliclazide was not borne out statistically, the reductions in HbA (1c) were similar over a two year period and vildagliptin had significant benefits in terms of less weight gain and less hypoglycemia.